Lipid-lowering therapies may have a potential for venous thromboembolism prevention, particularly in high-intensity dosing and in combination therapy. Read more in #EHJ. doi.org/10.1093/eurhea… #lipid #thromboembolism #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

Sharing International Experiences in Hospital at Home 🏠🏥 🇪🇸 🇦🇷 🇺🇸 🇨🇦 🇸🇬 stam ehad Álvaro Dubois Silva

Validation➡️cohort of acute PE patients from 🇨🇳 Compared to the Geneva, modified FAST, and Bova score, the AUCs for predicting 30-day death of sPESI and RIETE score were⬆️: 0.712 (95 % CI, 0.680, 0.743) and 0.723 (95 % CI, 0.691, 0.755), respectively. David Jiménez 🇪🇸 manuel monreal

Álvaro Dubois Silva manuel monreal My comment here: pubmed.ncbi.nlm.nih.gov/38599925/

Nueva guía IDSA 🎉🥳🎊🆕 de INFECCIONES #GramNegativosResistentes, señalamos los principales CAMBIOS respecto a la de 2023 👇🏻📸👀 Cambios en #BLEE, #AmpCinducible, #Carbapenemasas, #PseudomonasDTR, #CRAB🦀 y #Smaltophilia. Lectura obligada!🙇🏻‍♂️📖 🔗🆓👉🏻idsociety.org/practice-guide…

🚨 IPDMA of ~2700 pts w early discharge after PE, ✅the utility of sPESI or Hestia for safe discharge European Society of Cardiology Journals Erik Klok David Jiménez 🇪🇸 . In an accompanying Editorial, Kushal Kadakia & I suggest: 🏡is where 🫀(🫁) is: tinyurl.com/59jvs6ky Paper: tinyurl.com/3cyxw2m5

Venous thromboembolism in pregnancy and postpartum: an illustrated review RPTH rpthjournal.org/article/S2475-…

Narrative review explores how to manage use of DOACs—apixaban, rivaroxaban, edoxaban, and dabigatran—in patients undergoing surgical and nonsurgical procedures to decrease risks of bleeding and thromboembolism. ja.ma/4fIm1hL

⚠️ Coming soon our humble contribution to this New Special Issue edited by Luis Ortega Paz 💉🫀 🫁 💊 Stay tuned! 🔍 Behnood Bikdeli

#Statin use and mortality in patients with deep vein thrombosis. Data from the #RIETE Registry sciencedirect.com/science/articl…

Much debate & interesting ongoing studies RE the choice of advanced therapies in pts w #PulmonaryEmbolism. How do we use anticoagulation in these pts? 🤔 Our review of A/C regimens CardiologyClinics , great work by Álvaro Dubois Silva! sciencedirect.com/science/articl… #CardioTwitter #HemeTwitter

VTE recurrence after discontinuing anticoagulation in patients with VTE after receiving the vaccine against COVID-19 The #RIETEregistry experience appearing soon in EJCI

Incidence of pregnancy related pulmonary embolism in Spain 2016-2021: ... sciencedirect.com/science/articl…

Submit your abstract for #WHAHC2025 and share your groundbreaking work with global leaders at the only international event dedicated to Hospital at Home. 🌐 🗓️Submit your abstract before the final deadline - 12 September 2024. 👉 whahc.kenes.com/abstract-submi… #HaH #WHAHC

The OCEANIC-AF randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation. Full trial results: nej.md/473TRdc #ESCardio

Original Article: Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease (EPIC-CAD) nej.md/3Z1D1d3 Editorial: Atrial Fibrillation and Stable Coronary Artery Disease nej.md/3T5MV9G #ESCardio | European Society of Cardiology

Waouh, what a program again 😍 Thanks to all the speakers for this amazing PE meeting David Jiménez 🇪🇸 M Righini Saskia Middeldorp and Mahé Isabelle 👍

Starting with the GREAT David Jiménez 🇪🇸 How do you stratify patients with PE? 🇪🇸